Afacifenacin Fumarate(Afacifenacin Fumarate) - 药物靶点：ENaC x mAChRs_在研适应症：夜尿_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Afacifenacin

靶点

ENaC x mAChRs

作用机制

ENaC调节剂(上皮细胞钠离子通道调节剂)、mAChRs拮抗剂(毒蕈碱型乙酰胆碱受体家族拮抗剂)

治疗领域

其他疾病

在研适应症

夜尿

非在研适应症

膀胱过度活动症综合征膀胱过度活动症

原研机构

Sumitomo Pharma Co., Ltd.

在研机构

Sumitomo Pharma Co., Ltd.

非在研机构

Sumitomo Pharma America, Inc.Sumitomo Dainippon Pharma America, Inc.

Nippon Shinyaku Co., Ltd.

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

分子式C27H26F3N3O2

InChIKeyIJUMFEAYOMCXAQ-VWLOTQADSA-N

CAS号877606-63-8

查看全部结构式(2)

关联

3

项与 Afacifenacin Fumarate 相关的临床试验

JPRN-JapicCTI-101261 / Unknown status临床2期

A Randomized, Double-Blind, Parallel-Group Study of SMP-986 in Patients with Overactive Bladder [Phase 2 Study]

开始日期2010-09-01

申办/合作机构

Sumitomo Pharma Co., Ltd.

JPRN-jRCT2080221224 / Unknown status临床2期

A Randomized, Double-Blind, Parallel-Group Study of SMP-986 in Patients with Overactive Bladder [Phase 2 Study]

开始日期2010-09-01

申办/合作机构

Sumitomo Pharma Co., Ltd.

NCT00409539 / Completed临床2期

A 10-week Randomised, DB, PG, PC Phase 2 Study to Investigate the Extent of Symptom Relief and the Safety and Tolerability of SMP-986 (20, 40, 80 and 120 mg) Administered Once Daily for 8 Weeks to Patients With Overactive Bladder Syndrome

SMP-986 is a compound being developed for the treatment of overactive bladder syndrome (OABS). This clinical study is designed to test the hypothesis that SMP-986 at doses of 20mg, 40mg, 80mg or 120mg provides greater symptom relief in OABS compared to placebo. The hypothesis will be tested by measuring the change in mean voids/24 hrs after treatment with SMP-986 compared to placebo, as well comparing the change in: the severity of urgency episodes, mean number of urgency episodes/24 hr, mean number of incontinence episodes/24 hr and the mean void volume/void between SMP-986 and placebo.

开始日期2006-12-01

申办/合作机构

Sumitomo Pharma America, Inc.

[+5]

100 项与 Afacifenacin Fumarate 相关的临床结果

登录后查看更多信息

100 项与 Afacifenacin Fumarate 相关的转化医学

登录后查看更多信息

100 项与 Afacifenacin Fumarate 相关的专利（医药）

登录后查看更多信息

2

项与 Afacifenacin Fumarate 相关的文献（医药）

2022-01-01·Current Therapeutic Research

Drugs Currently Undergoing Preclinical or Clinical Trials for the Treatment of Overactive Bladder: A Review

Review

作者: Joseph, Silvia ; Peedicayil, Jacob ; Maria, Steffi A

BackgroundOveractive bladder (OAB) is a common clinical condition for which current drug treatment comprises drugs blocking the cholinergic nerve supply, or augmenting the adrenergic nerve supply, to the detrusor muscle of the urinary bladder. Current treatments have drawbacks, including lack of efficacy and the development of adverse effects in some patients. Hence, new and better drugs for treating OAB will be clinically useful.ObjectiveThis review is meant to provide information on drugs currently undergoing preclinical or clinical trials for the treatment of OAB published in journal articles or elsewhere.MethodsThe cited articles were retrieved from PubMed and Google Scholar from January 1, 1990, to December 31, 2021. The search terms used were contraction or contractility, detrusor, inhibition, isolated or in vitro, in vivo, overactive bladder, and relaxant effect or relaxation.ResultsThere are 4 classes of new drugs under various stages of development for the treatment of OAB. These are drugs acting on the autonomic nerve supply to the detrusor muscle of the urinary bladder that include the anticholinergics tarafenacin and afacifenacin and the β₃ adrenoceptor agonists solabegron and ritobegron; drugs acting on ion channels in the detrusor muscle (eg, potassium channel openers and calcium channel blockers), drugs acting on cellular enzymes like phosphodiesterase-5 inhibitors and Rho kinase inhibitors, and drugs acting on miscellaneous targets (eg, pregabalin and trimetazidine).ConclusionsDrugs currently used to treat OAB target only the cholinergic and adrenergic cellular signalling pathways. There are many other drugs under trial targeting other cellular pathways that may be useful for treating OAB. Their approval for clinical use might improve the treatment of patients with OAB. (Curr Ther Res Clin Exp. 2022; 83:XXX-XXX).

2014-10-01·Expert Opinion on Investigational Drugs2区 · 医学

Phase II drugs that target cholinergic receptors for the treatment of overactive bladder

2区 · 医学

Review

作者: Ilias Giarenis ; Martino Maria Zacche ; Linda Cardozo

INTRODUCTIONOveractive bladder (OAB) is a term used to describe the symptom syndrome of urgency, with or without urgency incontinence, usually associated with frequency and nocturia. Antimuscarinics are the most widely prescribed class of drugs for OAB, although their systemic adverse effects limit their use in clinical practice as compliance. This has led to developments in the field.AREAS COVEREDIn this review, the authors describe Phase II drugs that target cholinergic receptors. First, the authors present the new antimuscarinics (tarafenacin and afacifenacin). This is followed by reports on a combination drug (tolenix) containing a muscarinic antagonist (tolterodine) associated with a muscarinic agonist (pilocarpine). Further, the authors discuss the trials of well-known drugs in either new combination therapy (solifenacin and mirabegron) or with new routes of delivery (oxybutynin vaginal ring). Finally, the authors examine the option of targeting nicotinic acetylcholine receptors (dexmecamylamine).EXPERT OPINIONDifferent strategies have been adopted to improve the efficacy and tolerability of therapeutics for OAB. Nicotinic receptors represent a novel therapeutic target; however, it is unlikely that antimuscarinic agents will be replaced as standard first-line therapy in the near future.

100 项与 Afacifenacin Fumarate 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
夜尿	临床2期	-	Sumitomo Pharma Co., Ltd.	-
夜尿	临床2期	日本	Nippon Shinyaku Co., Ltd.	-
膀胱过度活动症	临床2期	日本	Sumitomo Pharma Co., Ltd.	-
膀胱过度活动症	临床2期	欧盟	Sumitomo Pharma Co., Ltd.	-
膀胱过度活动症综合征	药物发现	拉脱维亚	Sumitomo Pharma America, Inc.	2006-12-01
膀胱过度活动症综合征	药物发现	法国	Sumitomo Pharma America, Inc.	2006-12-01
膀胱过度活动症综合征	药物发现	波兰	Sumitomo Dainippon Pharma America, Inc.	2006-12-01
膀胱过度活动症综合征	药物发现	西班牙	Sumitomo Dainippon Pharma America, Inc.	2006-12-01
膀胱过度活动症综合征	药物发现	爱沙尼亚	Sumitomo Dainippon Pharma America, Inc.	2006-12-01
膀胱过度活动症综合征	药物发现	立陶宛	Sumitomo Dainippon Pharma America, Inc.	2006-12-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00409539 (CTgov)	临床2期	膀胱过度活动症综合征	550	Placebo (Placebo)	鑰顧觸構簾繭鏇網憲鬱(壓鹹艱齋獵餘顧鏇構遞) = 鏇鏇積衊鏇衊鹹鹽膚淵衊淵廠觸鹽獵鹹築願廠 (糧鬱觸遞鬱壓壓觸遞鏇, 襯鑰衊鹽選齋製齋鏇夢 ~ 壓艱繭艱膚構鑰願廠廠) 更多	-	2014-12-10
				SMP-986 (20mg Dose of SMP-986)	鑰顧觸構簾繭鏇網憲鬱(壓鹹艱齋獵餘顧鏇構遞) = 衊憲衊醖淵餘鬱窪鑰觸衊淵廠觸鹽獵鹹築願廠 (糧鬱觸遞鬱壓壓觸遞鏇, 襯鑰簾鬱觸鹹衊艱蓋築 ~ 範繭醖觸網顧餘簾獵積) 更多